Newswise — The deadly fungus, Candida auris, which has sickened at least 28 people in the United States, and has been reported in Illinois, Maryland, Massachusetts, and New Jersey, has been systemically studied for the first time in a study published in Antimicrobial Agents and Chemotherapy, by Mahmoud Ghannoum, PhD, MBA, FIDSA, Professor and Director of the Center for Medical Mycology in the Department of Dermatology at Case Western Reserve School of Medicine, and University Hospitals Cleveland Medical Center.
The comprehensive study also provides evidence that a new investigational drug (SCY-078) may help to cure these infections.
“This emerging fungal species has started to infect patients globally, causing invasive infections that are associated with a high death rate,” said Mahmoud Ghannoum, PhD, MBA, FIDSA, “It is multidrug-resistant, and some strains isolated from patients are resistant to all commercially available antifungal drugs. Multidrug-resistance used to be reported for bacteria only, and now we must add fungi to the list.”
Ghannoum led the investigation of 16 strains of C. auris collected from infected patients in Germany, Japan, Korea, and India. The researchers tested the isolates against a battery of 11 drugs, belonging to different classes of antifungals, to identify drug concentrations that could combat infection. While most samples proved at least partially resistant to drugs tested, low concentrations of an investigational drug (SCY-078) “severely distorted” the fungus and impaired its growth, providing an important step towards the development of this drug to treat C. auris infections. Fungi exposed to the drug could not divide, suggesting it could halt infections or limit their spread. Ghannoum’s study is the first to provide details related to the effects of the investigational drug on C. auris.
The fungus lurks on catheters in intensive care units, where it forms highly drug-resistant communities, or biofilms. Ghannoum’s team exposed fungi in the laboratory to silicone surfaces mimicking catheters. Under high-powered microscopes, they found C. auris formed relatively thin biofilms that weakened when exposed to the investigational drug. The findings were strain-dependent, but suggest applicability for the new drug to combat catheter-associated infections in particular.
Previous studies have shown the drug is effective against other Candida species that cause catheter-associated infections, including C. albicans and C. tropicalis. Said Ghannoum, “This drug is especially promising because of its broad anti-Candida activity, including activity against drug-susceptible and resistant strains.”
The study is also the first to report C. auris does not germinate and produce spores like other fungi, a surprise given its ability to rapidly spread in hospitals. The researchers also discovered only certain strains produce destructive enzymes that commonly help fungi establish infections in body tissue. Despite these apparent weaknesses, the fungus is able to maintain extreme drug-resistance and infect patients. According to the paper, the “multidrug-resistant phenotype of C. auris comes with a major fitness cost.”
Ghannoum’s research provides a foundation for clinical trials to further study the investigational drug and informs doctors desperate for new ways to treat infections caused by C. auris. Said Ghannoum, “Understanding the virulence of C. auris and showing that the investigational drug is effective may lead to the development of new medications to combat this emerging health threat.”
The Centers for Disease Control and Prevention is actively tracking C. auris infections. Said Ghannoum, “Eradication of Candida auris from hospitals is very difficult and in some cases has led to closing hospital wards.” People staying in hospitals for extended periods of time are most at risk. Laboratory workers who identify the species in a patient sample are encouraged to contact state or local public health authorities, or [email protected]
This research was supported in part by Scynexis Inc.; the National Institutes of Health (R01DE024228 to M.A.G. and P.K.M.); and the Swagelok Center for Surface Analysis of Materials, Skin Diseases Research Center (NIAMS P30 AR03970), and Confocal Scanning Laser Microscopy Core of the Genetics Department at Case Western Reserve University.
For more information about Case Western Reserve University School of Medicine, please visit: http://case.edu/medicine.
Journal Link: Antimicrobial Agents and Chemotherapy, March-2017
MEDIA CONTACTRegister for reporter access to contact details
R01DE024228; NIAMS P30 AR03970; Antimicrobial Agents and Chemotherapy, March-2017